Literature DB >> 18690432

[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Ludwig Dubois1, Willy Landuyt, Lieselotte Cloetens, Anne Bol, Guy Bormans, Karin Haustermans, Daniel Labar, Johan Nuyts, Vincent Grégoire, Luc Mortelmans.   

Abstract

PURPOSE: The aim of this investigation was to quantitatively compare the novel positron emission tomography (PET) hypoxia marker 2-(2-nitroimidazol-1-yl)-N-(3[(18)F],3,3-trifluoropropyl)acetamide ([(18)F]EF3) with the reference hypoxia tracer [(18)F]fluoromisonidazole ([(18)F]FMISO).
METHODS: [(18)F]EF3 or [(18)F]FMISO was injected every 2 days into two separate groups of rats bearing syngeneic rhabdomyosarcoma tumours. In vivo PET analysis was done by drawing regions of interest on the images of selected tissues. The resulting activity data were quantified by the percentage of injected radioactivity per gram tissue (%ID/g) and tumour to blood (T/B) ratio. The spatial distribution of radioactivity was defined by autoradiography on frozen tumour sections.
RESULTS: The blood clearance of [(18)F]EF3 was faster than that of [(18)F]FMISO. The clearance of both tracers was slower in tumour tissue compared with other tissues. This results in increasing T/B ratios as a function of time post tracer injection (p.i.). The maximal [(18)F]EF3 tumour uptake, compared to the maximum [(18)F]FMISO uptake, was significantly lower at 2 h p.i. but reached similar levels at 4 h p.i. The tumour uptake for both tracers was independent of the tumour volume for all investigated time points. Both tracers showed heterogeneous intra-tumoural distribution.
CONCLUSIONS: [(18)F]EF3 tumour uptake reached similar levels at 4 h p.i. compared with tumour retention observed after injection of [(18)F]FMISO at 2 h p.i. Although [(18)F]EF3 is a promising non-invasive tracer, it is not superior over [(18)F]FMISO for the visualisation of tumour hypoxia. No significant differences between [(18)F]EF3 and [(18)F]FMISO were observed with regard to the intra-tumoural distribution and the extra-tumoural tissue retention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690432     DOI: 10.1007/s00259-008-0907-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Elisabeth Ralfkiaer; Lena Specht
Journal:  Hematol Oncol       Date:  2006-09       Impact factor: 5.271

2.  Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.

Authors:  J S Rasey; P D Hofstrand; L K Chin; T J Tewson
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

3.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.

Authors:  Kaisa Lehtiö; Vesa Oikonen; Samuel Nyman; Tove Grönroos; Anne Roivainen; Olli Eskola; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-30       Impact factor: 9.236

5.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.

Authors:  Morand Piert; Hans-Jürgen Machulla; Maria Picchio; Gerald Reischl; Sybille Ziegler; Piyush Kumar; Hans-Jürgen Wester; Roswitha Beck; Alexander J B McEwan; Leonard I Wiebe; Markus Schwaiger
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

6.  Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages.

Authors:  Kirsten Skov; Hans Adomat; Mary Bowden; Wieslawa Dragowska; Martin Gleave; Cameron J Koch; Janet Woo; Donald T T Yapp
Journal:  Radiat Res       Date:  2004-11       Impact factor: 2.841

7.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.

Authors:  J S Rasey; Z Grunbaum; S Magee; N J Nelson; P L Olive; R E Durand; K A Krohn
Journal:  Radiat Res       Date:  1987-08       Impact factor: 2.841

8.  The detection and measurement of hypoxic cells in solid tumors.

Authors:  J D Chapman
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

Review 9.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

10.  Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing.

Authors:  Lise Bentzen; Susanne Keiding; Michael R Horsman; Tove Grönroos; Søren B Hansen; Jens Overgaard
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

View more
  15 in total

1.  Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.

Authors:  Olli Eskola; Tove J Grönroos; Sarita Forsback; Johanna Tuomela; Gaber Komar; Jörgen Bergman; Pirkko Härkönen; Merja Haaparanta; Heikki Minn; Olof Solin
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 2.  Imaging hypoxia to improve radiotherapy outcome.

Authors:  Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 3.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

4.  Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.

Authors:  Ludwig J Dubois; Natasja G Lieuwes; Marco H M Janssen; Wenny J M Peeters; Albert D Windhorst; Joseph C Walsh; Hartmuth C Kolb; Michel C Ollers; Johan Bussink; Guus A M S van Dongen; Albert van der Kogel; Philippe Lambin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

Review 5.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

6.  Evaluation of hypoxic tissue dynamics with 18F-FMISO PET in a rat model of permanent cerebral ischemia.

Authors:  Santiago Rojas; José Raul Herance; Sergio Abad; Xavier Jiménez; Deborah Pareto; Alba Ruiz; Èlia Torrent; Francisca P Figueiras; Foteini Popota; Francisco J Fernández-Soriano; Anna M Planas; Juan D Gispert
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 7.  Multimodality imaging of hypoxia in preclinical settings.

Authors:  R P Mason; D Zhao; J Pacheco-Torres; W Cui; V D Kodibagkar; P K Gulaka; G Hao; P Thorpe; E W Hahn; P Peschke
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 2.346

Review 8.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 9.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

10.  (18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.

Authors:  Ang Gao; Shijiang Wang; Zheng Fu; Xindong Sun; Jinming Yu; Xue Meng
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.